Using Arterial–venous Analysis to Characterize Cancer Metabolic Consumption in Patients
Nanxiang Xiong,Xiaofei Gao,Hongyang Zhao,Feng Cai,Fang-cheng Zhang,Ye Yuan,Weichao Liu,Fangping He,Lauren G. Zacharias,Hong Lin,Hieu S. Vu,Chao Xing,Dong-Xiao Yao,Fei Chen,Benyan Luo,Wenzhi Sun,Ralph J. DeBerardinis,Hao Xu,Woo-ping Ge
DOI: https://doi.org/10.1038/s41467-020-16810-8
IF: 16.6
2020-01-01
Nature Communications
Abstract:Understanding tumor metabolism holds the promise of new insights into cancer biology, diagnosis and treatment. To assess human cancer metabolism, here we report a method to collect intra-operative samples of blood from an artery directly upstream and a vein directly downstream of a brain tumor, as well as samples from dorsal pedal veins of the same patients. After performing targeted metabolomic analysis, we characterize the metabolites consumed and produced by gliomas in vivo by comparing the arterial supply and venous drainage. N-acetylornithine, D-glucose, putrescine, and L-acetylcarnitine are consumed in relatively large amounts by gliomas. Conversely, L-glutamine, agmatine, and uridine 5-monophosphate are produced in relatively large amounts by gliomas. Further we verify that D-2-hydroxyglutarate (D-2HG) is high in venous plasma from patients with isocitrate dehydrogenases1 ( IDH1 ) mutations. Through these paired comparisons, we can exclude the interpatient variation that is present in plasma samples usually taken from the cubital vein.